17,261 trials
Retinal Disease
Primary: Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at Two Years Compared to Baseline — 0 ETDRS letters
Severe Sepsis · Septic Shock
Primary: Ventilator-free Days (VFDs) Over 28 Days — 21.0; 17.5; 19.0 Days
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — -0.61; -0.08 percent of HbA1c in blood — p=0.010
Environmental Carcinogenesis
Primary: Effect of Treatment on Levels of Air Toxics Mercapturic Acids Over Intervention Period — 1.700; 1.065 pmol/mg creatinine
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Multiple Myeloma · Plasma Cell Neoplasm
Primary: Tolerance for Human Immune Globulin Intravenous (IGIV), as Reflected by the Number and Severity of Toxicity Incidents Occurring in Ten Patients Receiving at Least One…
Chronic Hepatitis B
Primary: Percentage of Participants With HBV Recurrence Prior to or at Week 72 — 0; 0 percentage of participants
Coronary Artery Disease (CAD)
Primary: Number of Participants With Reversible Defects — 84; 16; 100; 1 participants
HIV Infections · AIDS
Primary: Safety — 0; 0 participants
Myelodysplastic Syndrome
Primary: The Overall Improvement Rate — 23.3; 22.7; 16.3; 0 Percentage of Participants
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 — 0.029; 0.120; 0.127; 0.138 Liters — p=<0.001
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Overall Response Rate (Complete and Partial) — 77.50 percentage of participants
Diabetes Mellitus, Type 1
Primary: Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) — -0.28; -0.46 pmol/mL — p=0.002
Myelodysplastic Syndrome
Primary: Combined Overall Response Rate (ORR) — 3; 2; 5 participants
Recurrent Endometrial Carcinoma
Primary: 6 Month Progression-free Survival — 18 participants